Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

1646649

registered interest
date	22/06/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Radiotherapy: Health Professions:
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will include provisions in the NHS workforce plan to increase the nuclear medicines workforce; and what steps he is taking to ensure the adequacy of supply of that workforce to meet future demand for (a) molecular radiotherapy and (b) other treatments.
tabling member constituency	Mid Derbyshire
tabling member printed	Mrs Pauline Latham
uin	190787
answer	answer is ministerial correction date of answer 27/06/2023 answer text <p>The Government has committed to publishing the Long-Term Workforce Plan shortly. This will include projections for the number of doctors, nurses and other professionals that will be needed, taking full account of improvements in retention and productivity. This plan will help ensure that we have the right numbers of staff, with the right skills, to transform and deliver high quality services fit for the future.</p><p>NHS England are currently leading work to revise the Brachytherapy and Molecular Radiotherapy Service Specification and to understand current service readiness to expand access to new molecular radiotherapy treatments, should they be approved by National Institute for Health and Care Excellence.</p> answering member constituency Colchester answering member printed Will Quince question first answered 27/06/2023 15:27:28 answering member 4423 label Biography information for Will Quince
tabling member	4025 label Biography information for Mrs Pauline Latham

1646476

registered interest
date	21/06/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Radiotherapy
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment his Department has made of regional variations in the provision of molecular radiotherapy.
tabling member constituency	Mid Derbyshire
tabling member printed	Mrs Pauline Latham
uin	190613
answer	answer is ministerial correction date of answer 30/06/2023 answer text <p>Molecular radiotherapy is currently commissioned alongside brachytherapy via a national service specification. There are currently 38 trusts in England that are commissioned to deliver these services however, given the spectrum of treatments available under this service specification, there is some variation in what each provider offers.</p><p>For this reason, NHS England is developing a standalone molecular radiotherapy service specification. This will clarify the service model and review demand and access arrangements. The service specification will also take into account any future developments in treatment technologies and recommendations made by the National Institute for Health and Care Excellence.</p> answering member constituency Faversham and Mid Kent answering member printed Helen Whately question first answered 30/06/2023 11:19:32 answering member 4527 label Biography information for Helen Whately
tabling member	4025 label Biography information for Mrs Pauline Latham

1537877

registered interest
date	01/11/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Aortic Dissection
house id	1
legislature	25259 pref label House of Commons
question text	What steps he is taking to improve (a) health outcomes and (b) early diagnosis for people with aortic dissections.
tabling member constituency	Mid Derbyshire
tabling member printed	Mrs Pauline Latham
uin	901967
answer	answer is ministerial correction date of answer 01/11/2022 answer text <p>In March 2022, NHS England launched an Aortic Dissection Toolkit to support the implementation of robust clinical pathways to identify and manage both Type A and Type B aortic dissection.</p><p>All English regions are working with the Cardiac Pathways Improvement Programme to improve diagnosis and treatment.</p> answering member constituency Faversham and Mid Kent answering member printed Helen Whately question first answered 01/11/2022 17:16:59 answering member 4527 label Biography information for Helen Whately
tabling member	4025 label Biography information for Mrs Pauline Latham

1486608

registered interest
date	05/07/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Accident and Emergency Departments: Standards
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to help reduce waiting times at emergency departments for (a) patients and (b) ambulances with patients in (i) England and (ii) the University Hospitals of Derby and Burton NHS Foundation Trust.
tabling member constituency	Mid Derbyshire
tabling member printed	Mrs Pauline Latham
uin	31080
answer	answer is ministerial correction date of answer 18/07/2022 answer text <p>NHS England’s Urgent and Emergency Care Recovery 10 Point Action Plan includes an increased role for NHS 111 as the first point of triage, measures to improve patient flow through hospitals and reduce pressure on emergency departments and ensuring medically fit patients can be discharged as soon as possible.</p><p> </p><p>University Hospitals of Derby and Burton NHS Foundation Trust is extending its same day emergency care service to seven days a week and reducing demand on accident and emergency through expanding community rapid intervention services and collaborating with the local health and care system to increase primary care capacity. The Trust plans to develop its medical workforce, establish a frailty assessment area for elderly patients and maximise the use of its urgent treatment centre.</p> answering member constituency Lewes answering member printed Maria Caulfield question first answered 18/07/2022 11:24:15 answering member 4492 label Biography information for Maria Caulfield
tabling member	4025 label Biography information for Mrs Pauline Latham

1435244

registered interest
date	24/02/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Aortic Dissection: Research
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to increase research funding into aortic dissection.
tabling member constituency	Mid Derbyshire
tabling member printed	Mrs Pauline Latham
uin	129120
answer	answer is ministerial correction date of answer 01/03/2022 answer text <p>The Department funds research through the National Institute for Health Research (NIHR). The NIHR welcomes funding applications for research into any aspect of human health, including aortic dissection.</p><p>In December 2020, the Department convened a multidisciplinary group of experts and patient representatives together to identify high-priority research questions for aortic dissection. In response to an outcome paper from this workshop, the NIHR launched a call on ‘Early endovascular repair in type b uncomplicated sub-acute aortic dissection’ and is currently exploring the development of a brief to cover outstanding questions and signal the NIHR’s desire to commission research in this important area.</p> answering member constituency Lewes answering member printed Maria Caulfield question first answered 01/03/2022 15:58:34 answering member 4492 label Biography information for Maria Caulfield
tabling member	4025 label Biography information for Mrs Pauline Latham

1341414

registered interest
date	28/06/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Travel: Coronavirus
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what evidence has been provided to Ministers on the comparative effectiveness of (a) mandatory self-isolation and (b) a mandatory testing regime for arrivals into the UK from amber destinations for managing the risk to public health from covid-19.
tabling member constituency	Mid Derbyshire
tabling member printed	Mrs Pauline Latham
uin	23162
answer	answer is ministerial correction date of answer 13/07/2021 answer text <p>We are unable to provide the evidence provided to Ministers as it relates to the formulation of ongoing border policy and its release could prejudice decision making.</p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 13/07/2021 09:41:20 answering member 4380 label Biography information for Jo Churchill previous answer version 10932 answering member constituency Bury St Edmunds answering member printed Jo Churchill answering member 4380 label Biography information for Jo Churchill
tabling member	4025 label Biography information for Mrs Pauline Latham

1341416

registered interest
date	28/06/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Travel: Coronavirus
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether (a) he and (b) officials in his Department have had discussions with counterparts in the Department for Transport on permitting the use of NHS lateral flow tests for mandatory covid-19 testing for arrivals into the UK from (i) amber and (ii) green list destinations.
tabling member constituency	Mid Derbyshire
tabling member printed	Mrs Pauline Latham
uin	23163
answer	answer is ministerial correction date of answer 01/07/2021 answer text <p>Officials in the Department of Health and Social Care and the Department for Transport have discussed options for reducing the cost of travel testing, including whether National Health Service lateral flow tests could be used by arrivals from ‘amber’ and ‘green list’ countries. However, lateral flow tests are not permitted for most international arrivals as they are not suitable for identifying variants. Polymerase chain reaction testing of inbound travellers and genome sequencing of positive samples are crucial for disease surveillance and identification of potentially harmful variants.</p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 01/07/2021 17:01:07 answering member 4380 label Biography information for Jo Churchill
tabling member	4025 label Biography information for Mrs Pauline Latham

1327742

registered interest
date	25/05/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Yellow Card Scheme
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the extent of under-reporting of adverse drug reactions to the Yellow Card scheme.
tabling member constituency	Mid Derbyshire
tabling member printed	Mrs Pauline Latham
uin	7153
answer	answer is ministerial correction date of answer 07/06/2021 answer text <p>The reporting rate for spontaneous adverse drug reactions (ADR) is variable and can depend on a multitude of factors. Although some historical studies have estimated only 10% of ADRs are reported, the actual rate is unknown and variable because it is influenced by public awareness and seriousness of the event.</p> answering member constituency Mid Bedfordshire answering member printed Ms Nadine Dorries question first answered 07/06/2021 08:40:15 answering member 1481 label Biography information for Ms Nadine Dorries
tabling member	4025 label Biography information for Mrs Pauline Latham

1327743

registered interest
date	25/05/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Antibiotics: Side Effects
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how many and what proportion of patients who are prescribed fluoroquinolone antibiotics suffer adverse reactions in the form of (a) tendon injury, (b) mitochondrial dysfunction and (c) oxidative stress.
tabling member constituency	Mid Derbyshire
tabling member printed	Mrs Pauline Latham
uin	7154
answer	answer is ministerial correction date of answer 09/06/2021 answer text <p>The Yellow Card Scheme is the system used in the United Kingdom for reporting adverse drug reactions (ADRs). This acts as an early warning system for the identification of previously unrecognised adverse reactions and also provides valuable information on recognised ADRs, allowing the Commission on Human Medicines and Medicines and Healthcare products Regulatory Agency (MHRA) to identify and refine the understanding of risk factors that may affect the clinical management of patients.</p><p> </p><p>The following table shows spontaneous suspected ADR reports for fluoroquinolones in association with tendon injury, mitochondrial dysfunction and oxidative stress to 25 May 2021 in the UK.</p><p> </p><table><tbody><tr><td><p>Reaction</p></td><td><p>Number of reports</p></td></tr><tr><td><p>Tendon disorders*</p></td><td><p>1,381</p></td></tr><tr><td><p>mitochondrial cytopathy, mitochondrial toxicity, mitochondrial myopathy acquired</p></td><td><p>1</p></td></tr><tr><td><p>Oxidative stress</p></td><td><p>2**</p></td></tr></tbody></table><p> </p><p>Source: MHRA Sentinel database for Adverse Drug Reactions.</p><p> </p><p>Notes:</p><p> </p><p>*Tendon disorders includes 21 different relevant reaction terms.</p><p>**These reports are duplicates and have been subsequently merged on the database.</p><p> </p><p>The frequency of tendonitis range from 1 in 100 to less than 1 in 10,000, depending on the specific fluoroquinolone medicine. For the products that provide an estimate of the frequency of tendon rupture, this is listed as less than 1 in 10,000. Mitochondrial dysfunction and oxidative stress are among the possible mechanisms that might lead to tendon injury or other ADRs caused by fluoroquinolones, but this association is not fully understood and mitochondrial dysfunction and oxidative stress are not listed as ADRs in the product information for fluoroquinolones.</p><p> </p><p>The MHRA continues to review information about the safety of all medicines, including fluoroquinolones, and will take appropriate regulatory action as appropriate on the basis of new safety information. Serious side effects of fluoroquinolone antibiotics can be varied, potentially affecting several different parts of the body. An assessment of the potential merits of fluoroquinolone toxicity as a clinical diagnosis in response to tendon injury, mitochondrial dysfunction or oxidative stress has not been made.</p> answering member constituency Mid Bedfordshire answering member printed Ms Nadine Dorries grouped question UIN 7155 question first answered 09/06/2021 09:32:28 answering member 1481 label Biography information for Ms Nadine Dorries previous answer version 4612 answering member constituency Mid Bedfordshire answering member printed Ms Nadine Dorries answering member 1481 label Biography information for Ms Nadine Dorries
tabling member	4025 label Biography information for Mrs Pauline Latham

1327744

registered interest
date	25/05/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Antibiotics: Side Effects
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what recent assessment he has made of the potential merits of establishing fluoroquinolone toxicity as a diagnosis in response to (a) tendon injury, (b) mitochondrial dysfunction and (c) oxidative stress attributed by some patients to the use of that drug.
tabling member constituency	Mid Derbyshire
tabling member printed	Mrs Pauline Latham
uin	7155
answer	answer is ministerial correction date of answer 09/06/2021 answer text <p>The Yellow Card Scheme is the system used in the United Kingdom for reporting adverse drug reactions (ADRs). This acts as an early warning system for the identification of previously unrecognised adverse reactions and also provides valuable information on recognised ADRs, allowing the Commission on Human Medicines and Medicines and Healthcare products Regulatory Agency (MHRA) to identify and refine the understanding of risk factors that may affect the clinical management of patients.</p><p> </p><p>The following table shows spontaneous suspected ADR reports for fluoroquinolones in association with tendon injury, mitochondrial dysfunction and oxidative stress to 25 May 2021 in the UK.</p><p> </p><table><tbody><tr><td><p>Reaction</p></td><td><p>Number of reports</p></td></tr><tr><td><p>Tendon disorders*</p></td><td><p>1,381</p></td></tr><tr><td><p>mitochondrial cytopathy, mitochondrial toxicity, mitochondrial myopathy acquired</p></td><td><p>1</p></td></tr><tr><td><p>Oxidative stress</p></td><td><p>2**</p></td></tr></tbody></table><p> </p><p>Source: MHRA Sentinel database for Adverse Drug Reactions.</p><p> </p><p>Notes:</p><p> </p><p>*Tendon disorders includes 21 different relevant reaction terms.</p><p>**These reports are duplicates and have been subsequently merged on the database.</p><p> </p><p>The frequency of tendonitis range from 1 in 100 to less than 1 in 10,000, depending on the specific fluoroquinolone medicine. For the products that provide an estimate of the frequency of tendon rupture, this is listed as less than 1 in 10,000. Mitochondrial dysfunction and oxidative stress are among the possible mechanisms that might lead to tendon injury or other ADRs caused by fluoroquinolones, but this association is not fully understood and mitochondrial dysfunction and oxidative stress are not listed as ADRs in the product information for fluoroquinolones.</p><p> </p><p>The MHRA continues to review information about the safety of all medicines, including fluoroquinolones, and will take appropriate regulatory action as appropriate on the basis of new safety information. Serious side effects of fluoroquinolone antibiotics can be varied, potentially affecting several different parts of the body. An assessment of the potential merits of fluoroquinolone toxicity as a clinical diagnosis in response to tendon injury, mitochondrial dysfunction or oxidative stress has not been made.</p> answering member constituency Mid Bedfordshire answering member printed Ms Nadine Dorries grouped question UIN 7154 question first answered 09/06/2021 09:32:28 answering member 1481 label Biography information for Ms Nadine Dorries previous answer version 4615 answering member constituency Faversham and Mid Kent answering member printed Helen Whately answering member 4527 label Biography information for Helen Whately
tabling member	4025 label Biography information for Mrs Pauline Latham